For the roughly 30,000 Americans living with amyotrophic lateral sclerosis at any given time, the calendar is the cruelest part of the disease. Most patients die within three to five years of diagnosis, and the therapeutic shelf is sparse. Into that gap walks Canurta Therapeutics, a Brampton, Ontario biotech that says it will begin first-in-human trials in 2025 for CNR-401, a liquid botanical drug built from ten active compounds, including the hemp-derived flavonoid cannflavin A [Canurta.com/investor-summary-2].
The disease state matters here, and so does the standard of care. ALS today is managed, not cured. The two most widely prescribed drugs, riluzole (approved by the FDA in 1995) and edaravone (approved in 2017), extend survival by a matter of months in most studies. A third agent, AMX0035, was withdrawn from the U.S. market in 2024 after a confirmatory Phase 3 trial missed its endpoints. Tofersen reaches only the small subset of patients with SOD1 mutations. For the great majority of people newly diagnosed, the conversation with a neurologist still revolves around symptom management, multidisciplinary clinic visits, non-invasive ventilation, and feeding support. Any candidate that credibly slows progression would be meaningful, and any candidate that does so with a tolerable safety profile in a vulnerable, often elderly population would be more meaningful still.
The bet
Founder and CEO Akeem Gardner started Canurta in 2021 with a thesis that hemp biomass contains underexplored polyphenols with anti-inflammatory and neuroprotective properties, and that AI-assisted screening can move those compounds from leaf to lead faster than conventional botanical drug development [Canurta.com]. The company describes its discovery engine as PolyKye, a library and synergy-prediction layer designed to identify combinations of bioactives that work better together than alone [Canurta.com]. CNR-401 is the first product of that approach to reach the regulatory door. According to the company, the candidate has shown blood-brain barrier penetration and a favorable safety profile in mouse toxicology studies, and Canurta has filed both a Pre-IND submission and an Orphan Drug Application with the FDA [Canurta.com, 2025].
That regulatory posture matters. The FDA's Botanical Drug Development Guidance, last updated in 2016, created a defined pathway for multi-component plant-derived therapeutics, but only a handful of products have ever cleared it. Orphan designation, if granted, would bring seven years of U.S. market exclusivity, tax credits on clinical trial costs, and a waiver of the prescription drug user fee. None of that substitutes for clinical evidence, but it does shape the economics of a small company trying to run a neurology trial.
Why it could be big
Canurta has raised more than $13 million in combined equity, convertible debt, and non-dilutive funding [BioSpace], with a $5 million seed round closed in 2021 [Black Dollar Magazine] and roughly $3.22 million in non-dilutive capital reported by the company [Canurta.com]. Backers include the Accelerator Centre, the Waterloo-region incubator that has supported the company since its early days, and PharmaDrug, a publicly traded specialty pharma firm. The capital structure is unusual for a pre-clinical biotech, leaning heavily on grants and convertibles rather than a traditional Series A, which has let Gardner stretch the runway through pre-IND work.
Total capital raised | 13 | $M
Seed round (2021) | 5 | $M
Non-dilutive funding | 3.22 | $M
The upside case rests on two things. First, ALS is an indication where any disease-modifying signal in early trials commands attention from larger neurology-focused pharma companies, several of which have active business development mandates in neurodegeneration. Second, the PolyKye platform, if it works as described, would not be a single-asset story. Canurta has signaled pipeline expansion into broader neurological and inflammatory indications, and its operational footprint now includes cGMP botanical extraction capacity in Woodburn, Oregon, following its transition into the FSOil facility under the Canurta Naturals banner [Canurta.com]. That vertical integration is rare among seed-stage biotechs and could matter for chemistry, manufacturing, and controls (CMC) consistency, which is historically the hardest part of botanical drug approval.
The team and traction
Gardner, who holds a Bachelor of Laws with Honours from the University of Kent and completed adMare Academy's Executive Institute Cohort V [ZoomInfo], has built out a small scientific bench that includes Eric Soubeyrand as Research Associate and Pamela Kisun as Head of Operations [ZoomInfo]. Kelly Boddington, who co-authored a 2022 paper on bibenzyl synthesis in Cannabis sativa in a Wiley journal [Wiley Online Library, 2022], has served in a mentor and management capacity. Gardner is a member of the American Academy of Neurology and has been an active presence on the conference circuit, presenting at the Life Sciences Investor Forum in November 2024 [GlobeNewswire, 2024] and the SUNY Cannabis Conference in January 2025 [Canurta.com, 2025].
The honest counterfactual
What bears will say is straightforward: botanical drugs have a hard regulatory history, the FDA approval count for the category remains in the single digits, and pre-clinical safety in mice is a long way from a powered Phase 2 readout in ALS, an indication that has humbled far better-resourced programs. The cannabis-adjacent provenance of cannflavin A also invites scrutiny, since the field has produced more press releases than approved drugs. What bulls answer is that Canurta is pursuing the formal botanical pathway with Pre-IND and Orphan Drug filings already submitted [Canurta.com, 2025], that CNR-401's reported blood-brain barrier penetration addresses one of the standard failure modes for CNS candidates [Canurta.com], and that the company controls its own cGMP extraction, which de-risks the CMC questions that have historically tripped up botanical sponsors.
What to watch
The near-term milestone is the one Canurta has put on the record itself: dosing the first human subject with CNR-401 in 2025. An IND clearance from the FDA, formal Orphan Drug designation, and the design of the Phase 1 protocol (single ascending dose, multiple ascending dose, healthy volunteers versus ALS patients) will tell investors and clinicians more about the program's seriousness than any platform deck. A priced Series A, likely needed to fund a Phase 2 program, would be the second signal. For a disease where families count time in months, the question is not whether a botanical approach is novel. It is whether this particular ten-compound mixture, in this particular patient population, can produce a clinical signal worth the wait.
Pulse Raman covers biotech, digital health, and clinical AI for Startuply.